5 hours Anika Therapeutics (NASDAQ:ANIK) Rating Reiterated by Barrington ResearchMarketBeat
Barrington Research reaffirmed an “outperform” rating and set a $37.00 price target on shares of Anika Therapeutics in a research note on Tuesday.
XBarrington Research reaffirmed an “outperform” rating and set a $37.00 price target on shares of Anika Therapeutics in a research note on Tuesday.
X